Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 22/12/2025

4,560 CHF (+13,43%)

(+13,43%) 22/12/2025

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 13,43%
1 week1w 15,59%
1 maand1m 45,92%
3 maanden3m 22,25%
6 maanden6m 143,59%
1 jaar1j 524,66%
5 jaar5j -81,96%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

10 december 2025 · New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD · Persbericht

9 december 2025 · Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category · Persbericht

10 november 2025 · Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension · Persbericht

5 november 2025 · Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions · Persbericht

30 oktober 2025 · QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results · Persbericht

10 oktober 2025 · Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability · Persbericht

9 oktober 2025 · Idorsia launches an offering of registered shares – to fund the company to overall profitability · Persbericht

22 september 2025 · Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China · Persbericht

19 september 2025 · Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension · Persbericht

10 september 2025 · Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe